Pfizer Inc PFE:NYSE (Common Stock)

LastDaily Change / % ChangeDividend YieldVolumeAvg Volume (10 day)
34.47 0.22   0.64%3.74%26,117,87023.3M
Market data is delayed by at least 15 minutes.
Summary chart showing the current equity's performance of over the past 1 days
  • Advanced Charts
  • Embed the above chart in your blog or website

    Customize, copy, and then paste the generated code into your website.

Market is closed. Chart as of 02:59 PM ET 3/22/2017 (03:59 PM 3/22/2017 Eastern Standard Time)

Latest News Headlines for Pfizer Inc

Pfizer Invites Public to View and Listen to Webcast of May 2 Conference Call with Analysts

NEW YORK--(BUSINESS WIRE)--March 22, 2017-- Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, May 2, 2017. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's First Quarter 2017 Performance Report, to be issued that morning.

Options Traders: Get options trade ideas for Advanced Micro Devices, Comcast, Coca-Cola, Pfizer Inc. and Snap Inc.

CHICAGO, March 20, 2017 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMD, CMCSA, KO, PFE, and SNAP. To see the high-return covered-call trades uncovered by InvestorsObserver's analysts, read the InvestorsObserver's PriceWatch Alert by selecting the corresponding link.

Bristol-Myers Squibb and Pfizer Present Large -3-

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding product development. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb's business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2016, in our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

View more recent headlines

Peers Information HelpPFE Pfizer Inc vs. Peers

PFE
Pfizer Inc
5.45%
Roche Holding Ltd. (ADR)
10.09%
Novartis AG (ADR)
2.13%
Merck & Co., Inc.
8.56%
Bayer AG (ADR)
8.87%
PFE
Pfizer Inc
3.71%
Roche Holding Ltd. (ADR)
3.23%
Novartis AG (ADR)
3.66%
Merck & Co., Inc.
2.96%
Bayer AG (ADR)
2.52%
PFE
Pfizer Inc
0.64%
Roche Holding Ltd. (ADR)
0.43%
-0.27%
Novartis AG (ADR)
-0.64%
Merck & Co., Inc.
Bayer AG (ADR)
0.20%
Compare these stocks

Latest Annual and Quarterly SEC Filings

More Filings
10-K

This report contains detailed information about the company's business finances and management.

10-Q

Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)

Company Background

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines, as well as products for consumer healthcare. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.

http://www.pfizer.com

Loading...

collapse, right-facing arrow indicating collapsed view of sectionOverview

A table providing an overview of the stock
Bid | Size-- | --
Ask | Size-- | --
Price Open34.30
Previous Close34.25
Day High34.54
Day Low33.99
52 Week High8/1/2016 | 37.39
52 Week Low4/1/2016 | 29.41
% Off 52 Week High(7.81)%
% Off 52 Week Low17.21%
Beta (5 Yr)0.96
Volatility Avg3/22/2017 | 17.33
10-Day Avg. Volume23,348,495
Market data is delayed by at least 15 minutes.

collapse, right-facing arrow indicating collapsed view of sectionFundamentals

A table providing the fundamentals of the stock
EPS (TTM)12/31/2016 | 1.17
P/E Ratio12/31/2016 | 29.4
Market CapMega Cap | 205.3B
Shares Outstanding5.96B
Float6.0B

collapse, right-facing arrow indicating collapsed view of sectionDividends

A table providing information about the dividends of the stock
Dividend Yield3.74%
Ex-Date2/1/2017
Dividend Announcement12/12/2016
Date of Record2/3/2017
Payable$0.32 - QRTR
Payable Date3/1/2017

collapse, right-facing arrow indicating collapsed view of sectionShare Statistics

A table providing statistics about shares of the stock
Shares Short110.37M
Short Ratio3.9
Short % of Float1.86%
As of 2/28/2017
The performance data quoted represents past performance. Past performance does not guarantee future results. Current performance may be lower or higher than the performance quoted. Investment return and principal value of an investment will fluctuate and when redeemed, the investment may be worth more or less than their original cost.
The research, tools, and information provided will not include every security available to the public.